Combination therapy for treating cancer

1. A pack or container comprising: (i) a pharmaceutical composition comprising a compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein

each of R a and R b , independently, is H or C 1 -C 6 alkyl, or R a and R b , together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, wherein the C 1 -C 5 alkyl or 4 to 7-membered ring is optionally substituted with one or more -Q 3 -T 3 , in which Q 3 is a bond or unsubstituted or substituted C 1 -C 3 alkyl linker, and T 3 is H, halo, 4 to 7-membered heterocycloalkyl, C 1 -C 3 alkyl, OR d , COOR d , —S(O) 2 R d , or —NR d R e , in which each of R d and R e is independently H or C 1 -C 6 alkyl, or -Q 3 T 3 is oxo;

R 7 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q 5 -T 5 , in which Q 5 is a bond, C(O), C(O)NR k , NR k C(O), S(O) 2 , or C 1 -C 3 alkyl linker, R k being H or C 1 -C 6 alkyl, and T 5 is H, halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O) q R q in which q is 0, 1, or 2 and R q is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T 5 is optionally substituted with one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T 5 is H, halo, hydroxyl, or cyano; or -Q 5 -T 5 is oxo; and

R 8 is H, methyl, or ethyl; and

(ii) a pharmaceutical composition comprising rituximab.

2. The pack or container of claim 1 , further comprising (iii) a pharmaceutical composition comprising lenalidomide.

3. The pack or container of claim 1 , wherein the compound of Formula (IIa) is Compound 44:

or a pharmaceutically acceptable salt thereof.

4. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, which is optionally substituted with one or more -Q 3 -T 3 .

5. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahydrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, or morpholinyl, each of which is optionally substituted with one or more -Q 3 -T 3 .

6. The pack or container of claim 5 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form morpholinyl.

7. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 7 is 4 to 7-membered heterocycloalkyl optionally substituted with one or more -Q 5 -T 5 .

8. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 7 is piperidinyl, tetrahydropyranyl, cyclopentyl, or cyclohexyl, each optionally substituted with one -Q 5 -T 5 .

9. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 7 is tetrahydropyranyl.

10. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 8 is H, methyl, or ethyl.

11. A pack or container comprising: (i) a pharmaceutical composition comprising a compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein

each of R a and R b , independently, is H or C 1 -C 6 alkyl, or R a and R b , together with the N atom to which the are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, wherein the C 1 -C 6 alkyl or 4 to 7-membered ring is optionally substituted with one or more -Q 3 -T 3 , in which Q 3 is a bond or unsubstituted or substituted C 1 -C 3 alkyl linker, and T 3 is H, halo, 4 to 7-membered heterocycloalkyl, C 1 -C 3 alkyl, OR d , COOR d , —S(O) 2 R d , or —NR d R e , in which each of R d and R e is independently H or C 1 -C 6 alkyl, or -Q 3 T 3 is oxo;

R 7 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q 5 -T 5 , in which Q 5 is a bond, C(O), C(O)NR k , NR k C(O), S(O) 2 , or C 1 -C 3 alkyl linker, R k being H or C 1 -C 6 alkyl, and T 5 is H, halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O) q R q in which q is 0, 1, or 2 and R q is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T 5 is optionally substituted with one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T 5 is H, halo, hydroxyl, or cyano; or -Q 5 -T 5 is oxo; and

R 8 is H, methyl, or ethyl; and

(ii) a pharmaceutical composition comprising lenalidomide.

12. The pack or container of claim 11 , further comprising (iii) a pharmaceutical composition comprising rituximab.

13. The pack or container of claim 11 , wherein the compound of Formula (IIa) is Compound 44:

or a pharmaceutically acceptable salt thereof.

14. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, which is optionally substituted with one or more -Q 3 -T 3 .

15. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahydrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, or morpholinyl, each of which is optionally substituted with one or more -Q 3 -T 3 .

16. The pack or container of claim 15 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form morpholinyl.

17. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R 7 is 4 to 7-membered heterocycloalkyl optionally substituted with one or more -Q 5 -T 5 .

18. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R 7 is piperidinyl, tetrahydropyranyl, cyclopentyl, or cyclohexyl, each optionally substituted with one -Q 5 -T 5 .

19. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R 7 is tetrahydropyranyl.

20. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R 8 is H, methyl, or ethyl.